Long-term use of adalimumab as monotherapy after attainment of low disease activity with adalimumab plus methotrexate in patients with rheumatoid arthritis

Podobne zapisy

• Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone
  od: Keystone, Edward C, i wsp.
  Wydane: (2017)
• Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis
  od: Kavanaugh, Arthur, i wsp.
  Wydane: (2018)
• Treatment efficacy and methotrexate-related toxicity in patients with rheumatoid arthritis receiving methotrexate in combination with adalimumab
  od: Burmester, Gerd R, i wsp.
  Wydane: (2017)
• Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate
  od: Smolen, Josef S, i wsp.
  Wydane: (2018)
• Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response
  od: Fleischmann, Roy M, i wsp.
  Wydane: (2019)